In the Press
February 10, 2021

Risk-Averse Pharma Companies Get Creative to Invest in New Drugs (Bloomberg Law)

The pharmaceutical industry is poised to see a record number of deals in 2021 thanks in part to innovative agreements that aim to facilitate the development of new products, industry watchers say. Milestone deals are among the ways investors are looking to enter the biopharma space in 2021, with products like COVID-19 treatments and vaccines underway says Goodwin Life Sciences partner Andrew Harrow. Read the Bloomberg Law article here.